CARISMA THERAPEUTICS INC (CARM) Stock Analyst Ratings
USA - NASDAQ:CARM - US14216R1014 - Common Stock
0.1539 USD
-0.12 (-43.81%)
0.1181 USD
-0.04 (-23.26%)
ChartMill assigns a Buy % Consensus number of 80% to CARM. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 1.02. This target is 562.77% above the current price.
CARM was analyzed by 8 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about CARM.
In the previous month the buy percentage consensus was at a similar level.
CARM was analyzed by 8 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-08 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-04-01 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-01-17 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-01-13 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-12-16 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-12-12 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-12-12 | Baird | Downgrade | Outperform -> Neutral |
| 2024-12-11 | Evercore ISI Group | Downgrade | Outperform -> In-Line |
| 2024-12-10 | BTIG | Downgrade | Buy -> Neutral |
| 2024-12-09 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-11-25 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-18 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-11-11 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-11-07 | EF Hutton | Maintains | Buy -> Buy |
| 2024-10-30 | EF Hutton | Initiate | Buy |
| 2024-06-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-04-11 | BTIG | Initiate | Buy |
| 2024-04-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-10-03 | Capital One | Initiate | Overweight |
| 2023-09-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-07-06 | Evercore ISI Group | Initiate | Outperform |
| 2023-06-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-28 | Baird | Reiterate | Outperform -> Outperform |
| 2023-05-24 | HC Wainwright & Co. | Initiate | Buy |
| 2023-04-14 | Baird | Initiate | Outperform |
CARISMA THERAPEUTICS INC / CARM FAQ
What do analysts expect the price target to be for CARISMA THERAPEUTICS INC (CARM)?
8 analysts have analysed CARM and the average price target is 1.02 USD. This implies a price increase of 562.77% is expected in the next year compared to the current price of 0.1539.
Can you provide the consensus rating for CARISMA THERAPEUTICS INC stock?
The consensus rating for CARISMA THERAPEUTICS INC (CARM) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for CARM stock?
The number of analysts covering CARISMA THERAPEUTICS INC (CARM) is 8.